Surgical Treatment of Recurrent Shoulder Dislocations
Nova Scotia Health Authority · with Canadian Institutes of Health Research (CIHR), NYU Langone Health · NCT05564494
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 16–40 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 200
- US sites recruiting
- 1
- Study start
- April 25, 2023
- Record last updated
- May 4, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a pilot multi-centre, double blinded randomized controlled trial. The primary outcome of this pilot trial will be feasibility. Prior to conducting a large definitive trial, the investigators will conduct this pilot trial comparing arthroscopic Bankart repair with arthroscopic anatomic glenoid reconstruction (AAGR), evaluating recurrent dislocation rates and functional outcomes over a 24-month period. The feasibility objectives are: (1) to evaluate the investigators ability to recruit patients across multiple sites and (2) to assess study protocol adherence and ability to follow patients to 24 months. Clinical objectives for the pilot trial are exploratory only. The investigators wish to gather means and standard deviations for clinical outcomes to power their future definitive trial. The objectives of the definitive trial will include a comparison of patient-reported outcomes at the two-year post-operative time point, differences in recurrence rates, complication rates, functional shoulder assessments, and return to work/sport.
Being studied: Bankart Repair; Anatomic Glenoid Reconstruction
Conditions: Shoulder Instability
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Recurrent anterior glenohumeral dislocation (two or more incidents)
- Presence of glenoid and/or humerus bone loss on imaging (x Ray, CT or MRI)
Exclusion Criteria
- Uncontrolled diabetes (Hgb A1C >7%)
- Prior surgery of affected shoulder
- Pregnancy
- Multidirectional instability
- Posterior instability
- Paralysis of the shoulder
- Cancer
- Severe systemic illness
- Presence of massive rotator cuff tear
- Patients that present with \< 10% or > 25% bone loss under preoperative imaging.
- Generalized laxity (>5/9 Beighton Score)
Recruiting US locations
NYU Langone Health
New York, NY 10016
Site contact: Jade Refuerzo · 646-929-7800 · Jade.Refuerzo@nyulangone.org
Study contacts (from the official record)
- Matt Miller, PhD · 9024737626 · research@drivanwong.com
Similar studies in New York
All arthritis studies in New York →- RecruitingPhase 3
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
Medipost, Inc.
- Location
- Flushing, NY + 33 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With…
Amgen
- Location
- Orchard Park, NY + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda
- Location
- Brooklyn, NY + 45 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- New York, NY + 10 other US sites
- Eligibility basics
- Ages 2–17